Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
Key Highlights
- ➤INFARMED approves Cantanhede lab for in-house microbiological and chemical/physical testing
- ➤Tilray expects reduced batch-release costs and shortened testing timelines
- ➤Portugal facility strengthens international supply across Germany, UK, Poland, and Italy
- ➤Tilray-branded cannabis medicines expand in the UK through Lyphe Clinic and Dispensary
Expert Statements
Rajnish Ohri, President, International, Tilray Brands
“As regulated medical cannabis markets continue to mature, the companies best positioned to lead will be those that combine pharmaceutical-grade quality, regulatory discipline, and reliable global supply at scale. Tilray has built one of the world’s leading EU-GMP-certified medical cannabis operations, and this approval further strengthens our platform in Portugal by bringing advanced quality testing closer to cultivation and production. It gives us greater speed, control, and flexibility across our international supply chain while reinforcing the infrastructure and technical expertise required to serve patients, physicians, pharmacies, and commercial partners with trusted medical cannabis products in high-standard markets around the world.”
INFARMED approval authorizes Tilray Medical’s Cantanhede, Portugal facility to conduct microbiological and chemical/physical testing on-site, advancing pharmaceutical-grade quality control within its EU-GMP production platform
CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal’s National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.
Get started
Create a free account to read the full story.